Is Vertex Stock Safer Or Riskier Than A Year Ago?
For questions about this article or underlying research, email help@trefis.com.
If you own Vertex Pharmaceuticals (VRTX), you probably bought a profitable drug maker built on Trikafta, its best-selling medicine. On November 2, 2026, Vertex reported third-quarter results that include Crinetics, the company it bought to add the hormone drug Palsonify. A purchase like that is a good reason to look again at what you own. So is your Vertex stake carrying more risk today than it did last fall?
Slightly Riskier: Vertex Now Carries Net Debt
It is riskier, though only by a little: Vertex now owes more than it holds in cash and short-term investments. At the end of its third quarter on September 30, 2026, Vertex had $6.48 billion of total debt against $6.3 billion of cash and short-term investments. A year earlier, its cash and short-term investments exceeded its debt by $4.45 billion.
Vertex had held more cash than debt at the end of every quarter from at least December 2011 through June 2026. On a broader measure of its own, management counts about $9.8 billion of cash and investments at the end of the third quarter. That total exceeds the company’s debt, so the net debt shows up only on the narrower measure.
The debt is small for a company of Vertex’s size. Its total debt equals 4.7% of its market value at the November 4, 2026 close, against 19.2% for the S&P 500.
Vertex Borrowed To Help Pay For Crinetics
Vertex took on new debt to buy Crinetics. Management said on the November 2 call that Vertex raised $4.5 billion of term loans to fund part of the acquisition, and the company currently pays interest of about 4.8% on them.
Crinetics brought Vertex Palsonify, a once-daily oral drug for acromegaly, a rare hormone disease that management says affects about 20,000 patients in the US. Palsonify’s sales were about $24 million for the full third quarter. Vertex’s results include only the $10 million from September, after the deal closed. Updating its earlier range of $13.1 billion to $13.2 billion, management raised its 2026 revenue guidance to $13.15 billion to $13.25 billion and said the increase reflects the addition of Crinetics.
What Vertex’s New Debt Means For Your Money
For you as a holder, the cost shows up in Vertex’s 2026 profit. Management expects about $105 million of costs in 2026 tied to financing Crinetics, including the higher interest. In a full year, though, interest on the $4.5 billion of loans at today’s rate of about 4.8% comes to about $216 million. Management also expects $0.5 billion of Crinetics compensation and transaction costs for the year.
Your share of the company is still growing, though, and that is news a holder can like. Vertex’s diluted share count was 255 million in the third quarter, down from 258 million a year earlier. Vertex kept buying back stock through the deal, spending about $120 million in the third quarter out of $921 million so far in 2026. Management said its plan for using cash still sets money aside for buybacks. The third-quarter spending compares with about $801 million in the first half, so the pace slowed sharply.
Until the third quarter of 2026, you could count on Vertex holding more cash than debt at every quarter end. For now, you cannot. The risk you carry is still small, and it stays small as long as Vertex keeps earning far more than its new loans cost. In the third quarter, Vertex earned $654 million of net income against about $50 million of financing costs. Vertex’s net debt at the end of December 2026, in the report the company is expected to release in February 2027, is the figure to watch.
Who Is Watching Your Portfolio’s Risk When You’re Not?
Vertex Pharmaceuticals is one risk to keep an eye on, and most portfolios hold many. Watching all of them, day after day, is hard to do alone. Our partner advisory firm builds portfolios on Trefis research, starting with the HQ Portfolio, whose edge has been limiting losses when markets fall. Talk it through on a free 30-minute call, and bring your hardest questions.
Spot an error or want more like this? Tell us in 10 seconds.